New hope for advanced prostate cancer: combination therapy enters human trials
Disease control
Not yet recruiting
This early-stage trial tests the safety of combining a targeted radiation drug (lutetium DGUL) with an immunotherapy (pembrolizumab) in 30 men with metastatic castration-resistant prostate cancer. Participants receive either the radiation drug alone or both drugs together. The go…
Phase: PHASE1 • Sponsor: Cellbion Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC